UW–Madison Leading New Research Collaboration Aimed at Treating Idiopathic Pulmonary Fibrosis (IPF)

University of Wisconsin–Madison scientists are poised to gain a better understanding of how to treat a progressive scarring disease of the lungs that kills an estimated 40,000 people every year in the United States. Despite its status as a leading cause of death in the U.S., researchers still don’t understand exactly how and why the disease — known as idiopathic pulmonary fibrosis, or IPF — takes hold and progresses, and doctors have few effective therapies at their disposal. Now, an interdisciplinary group of researchers from UW–Madison’s Institute for Clinical and Translational Research, School of Medicine and Public Health, College of Engineering, and School of Pharmacy will investigate the biological processes that promote lung scarring. With the aid of artificial intelligence and advanced 3D modeling, they will also develop and refine new imaging techniques and drug delivery systems that could aid in halting disease progression.

Login Or Register To Read Full Story